Possible New Treatment for Spinal Cord Injuries Identified in Research Led by PVM Professor

Dr. Riyi Shi pictured

Research led by a Purdue Veterinary Medicine scholar shows that an experimental drug has promise as a potential therapy for spinal cord injuries in animal studies.  The compound, 4-aminopyridine-3-methanol, works in a similar way as a drug previously developed at Purdue, 4-aminopyridine (4-AP), which has been approved by the U.S. Food and Drug Administration to treat multiple sclerosis.

Dr. Riyi Shi, who holds a joint appointment as professor in Purdue Veterinary Medicine’s Department of Basic Medical Sciences, and in the Weldon School of Biomedical Engineering, was involved in the development of both drugs, and compared the two compounds in both cell cultures and animal models.  “For the first time, 4-aminopyridine-3-methanol is shown to restore function in chronic spinal cord injuries,” Dr. Shi says. “It also reduces neuropathic pain to a greater degree than 4-AP.

Dr. Shi further explains, “Because persistent chronic pain is a serious problem among patients with spinal cord injuries, 4-aminopyridine-3-methanol could potentially be used to reduce pain, independent of any motor benefits.”  He says an advantage of this drug is its broad therapeutic dosing range. “The minimum effective dose can be as low as 10 times less than 4-AP, but it can also be applied at a level that is five times as high.”

In spinal injuries even if the nerve fibers of the spinal cord itself, the axons, are intact, function can still be lost if there is damage to the fatty coating on the outside of nerve fibers, which is called the myelin sheath. When the myelin sheath is damaged, potassium channels underneath the coating open, disrupting the electrical signal. Both drugs work by closing these channels to restore the conduction of the axons.

“We are very encouraged by this preclinical study because about 10 years ago 4-AP, which is marketed as fampridine, dalfampridine, or Ampyra, was approved for MS, and both spinal cord injuries and MS share a similar mechanism of nerve signal conduction loss; they both could be caused by myelin damage,” Dr. Shi says. “The drug was approved for MS but not approved for spinal cord injuries because of concerns about potential toxicity and a narrow therapeutic dose range. So there is a big need for a better channel blocker.”

Dr. Shi and his team found that 4-aminopyridine-3-methanol is safer, more effective at closing the potassium channels — at least 50 percent more effective — and also much longer lasting.  The research is published in the May Journal of Neurotrauma, and was funded by the National Institutes of Health; the state of Indiana; the Science and Technology Commission of Shanghai Municipality, Shanghai, China; and grants from the Shanghai Bureau of Health, Shanghai, China.

Dr. Shi also is the co-founder of Neuro Vigor, a startup company with business interests of developing effective therapies for central nervous system neurodegenerative diseases and trauma.

Click here to view a complete news release about the research.

Writer(s): Steve Tally, steve@purdue.edu | pvmnews@purdue.edu

Recent Stories

“Paws Up” – brought to you by the PVM Wellness Committee

This week, our appreciation is extended to Dr. Dielson Vieira who is a clinical assistant professor in the Department of Basic Medical Sciences.

When Therapy Isn’t Enough

Emma Senter, a Purdue University Department of Psychological Sciences junior, has always considered herself an animal person. So, when she had the opportunity to join the Human-Animal Partnerships and Interactions (HAPI) Lab in the College of Veterinary Medicine, she jumped at the chance.

PVM Collaborates with Indianapolis Zoo to Host Emerging Conservationist Award Winner at Lynn Hall

Purdue veterinary students had a unique chance this week to hear first-hand from one of the world’s leading conservationists who is making a significant impact while still early in his career.  Through a collaborative arrangement with the Indianapolis Zoo, the College of Veterinary Medicine hosted a visit by Mwezi “Badru” Mugerwa, the winner of the 2025 Indianapolis Prize Emerging Conservationist Award, on Monday, September 29, so he could share his message with Purdue DVM students.

Career Fair Connects PVM Students with Future Opportunities

Close to 75 veterinary medical employers, ranging from individual veterinary practices to corporate enterprises, sent representatives to Purdue University for the College of Veterinary Medicine’s annual Career Fair for DVM and Veterinary Technology students. Held in the Purdue Memorial Union Ballrooms Friday afternoon, September 19, the event attracted a strong turnout of students excited to learn about future career opportunities.